MTRC has developed three reports on the key market access topics, including innovation funding, health technology assessment and funding frameworks for medical devices. These reports help to understand the relevance of these frameworks to certain types of medical technologies, including ENT technologies. This post provides some key facts about the HTA, funding and innovation payment landscape for ENT devices in Europe.

New material codes for extraction catheters were added to the List of reimbursable devices of the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) in September 2019.

MTRC continues releasing new seminars on the topics on market access. The seminar discusses key stakeholders, money flow, reimbursement in hospital and ambulatory settings, Nomenclature of medical services, specifics of reimbursement processes and the role of HTA.

MTRC continues releasing new seminars on the topics on market access. The seminar discusses key stakeholders, money flow, reimbursement in hospital and ambulatory settings, role of DRG and fee for service model, specifics of reimbursement processes and the role of HTA.

The fee negotiations for the coming year are over - the National Association of Statutory Health Insurance Physicians (KBV) and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) agreed on an increase in the monetary conversion factor for all medical and psychotherapeutic services in the amount of 1.52 percent. GKV-Spitzenverband and KBV have also agreed to sponsor the video consultations.

In August 2019, the Decision Forum conducted the meeting towards the funding decisions for new methods, where concluded that prehospital CT ("stroke ambulance") for early diagnosis and treatment of suspected stroke can be used within the framework of controlled studies with a sufficient number of patients. The protocol of the Decision Forum meeting was released on the website of the New Method.

MTRC has developed three reports on the key market access topics, including innovation funding, health technology assessment and funding frameworks for medical devices. These reports help to understand the relevance of these frameworks to certain types of medical technologies, including endoscopy technologies. This post provides some key facts about the HTA, funding and innovation payment landscape for endoscopy devices in Europe.

After a long time since the introduction of Healthcare Implementation Communique (SUT) for the first time (2007), the Reimbursement Commission made important changes to the SUT. The main changes relate to higher reimbursement fees for medical devices (reimbursement fees increased depending on the category from 5% to 100%).

In September 2019, the French High Authority for Health (HAS) has released an assessment report regarding the evaluation of total or partial robotic-assisted nephrectomy, compared to open surgery and conventional laparoscopic surgery. Due to the lack of any prospective comparative studies reporting robust results with relevant judgment criteria and collected with appropriate follow-up time, HAS could not comment on the expected service or the expected service improvement of robot-assisted nephrectomy compared to open surgery or conventional laparoscopic surgery.

MTRC has developed three reports on the key market access topics, including innovation funding, health technology assessment and funding frameworks for medical devices. These reports help to understand the relevance of these frameworks to certain types of medical technologies, including endocrine technologies. This post provides some key facts about the HTA, funding and innovation payment landscape for endocrine devices in Europe.

On the 2nd of September 2019, the Austrian HTA body, the Ludwig-Boltzmann Institute (LBI-HTA) has released a report on guideline recommendations comprising screening for diabetes mellitus.

In order to diagnose pre-eclampsia in pregnancy, two new markers were included in the EBM catalog in early October 2019. The statutory health insurances then will take over the costs for the determination of the PIGF concentration and the sFlt-1 / PIGF quotient. In addition, another tumor marker for ovarian cancer will be included in the EBM.